DDInter44 DDInter927
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Alfuzosin {u} (Compound) resembles {v} (Compound) Terazosin
Alfuzosin {u} (Compound) resembles {v} (Compound) Prazosin
Alfuzosin {u} (Compound) binds {v} (Gene) ADRA1A
Alfuzosin {u} (Compound) upregulates {v} (Gene) PAK1
Alfuzosin {u} (Compound) downregulates {v} (Gene) RBM34
Alfuzosin {u} (Compound) causes {v} (Side Effect) Coronary artery disease
Alfuzosin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Alfuzosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabilone
Alfuzosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Morphine
Alfuzosin {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Alfuzosin (Compound) resembles Terazosin (Compound)
Alfuzosin (Compound) resembles Prazosin (Compound)
Alfuzosin (Compound) binds ADRA1A (Gene)
Alfuzosin (Compound) upregulates PAK1 (Gene)
Alfuzosin (Compound) downregulates RBM34 (Gene)
Alfuzosin (Compound) causes Coronary artery disease (Side Effect)
Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Nabilone
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Alfuzosin may lead to a major life threatening interaction when taken with Cobicistat